港股異動|艾美疫苗早盤一度大升近39% 已較年內低點翻倍
艾美疫苗(6660.HK)早盤一度大升近39%,最高觸及7.95港元,已較年內低點翻倍。消息面上,隨着美聯儲降息週期開啟、央行宣佈降息降準等利好政策頻出,港股醫藥板塊連續多日反彈,艾美疫苗表現亮眼,近五個交易日股價接近翻倍。據介紹,目前,艾美目前擁有包括8款商業化疫苗,和21款在研疫苗產品,管線覆蓋全球前十大疫苗品種。此外,公司今年有3款重磅大單品疫苗產品即將申報上市,意味着公司即將迎來收穫期,業績拐點非常明確。有分析認為,隨着3款新產品上市,艾美疫苗的銷售收入有望達到50億元人民幣左右。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.